Senza5 Biotechnology

viTToria Biotherapeutics is a clinical-stage cell therapy company based in Philadelphia, focused on developing next-generation CAR-T cell therapies. The company's core technology, the Senza5™ platform, utilizes precision gene editing to disable CD5 signaling in T-cells, which prevents fratricide and enhances antitumor potency, expansion, and durability. Their lead candidate, VIPER-101, is currently in a Phase 1 clinical trial for the treatment of relapsed or refractory T-cell lymphoma. By combining genetic engineering with a proprietary five-day manufacturing process, Vittoria aims to deliver more effective and accessible treatments for aggressive hematologic malignancies, solid tumors, and autoimmune diseases.